Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), found exclusively in a subset of ALK-positive anaplastic large cell lymphoma, promotes tumorigenesis by exerting its constitutively active tyrosine kinase activity. Thus, characterization of the NPM-ALK-induced changes in the phosphoproteome will likely provide insights into the biology of this oncoprotein. To achieve this goal, we used a strategy of combining sequential affinity purification of phosphopeptides and LC/MS. GP293 cells transfected with either NPM-ALK or an NPM-ALK mutant with decreased tyrosine kinase activity (negative control) were used. We identified 506 phosphoproteins detectable in NPM-ALK-expressing cells but not in the negative control. Bioinformatics analysis revealed that these phosphoproteins carry a wide diversity of biological functions, some of which have not been described in association with NPM-ALK, such as the tumor necrosis factor (TNF)/Fas/tumor necrosis factor-related apoptosis-induced ligand (TRAIL) signaling pathway and the ubiquitin proteasome degradation pathway. In particular, modulations of the TNF/Fas/TRAIL pathway by NPM-ALK were supported by our antibody microarray data. Further validation of the TNF/Fas/TRAIL pathway was performed in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines with knockdown of NPM-ALK using short interference RNA, resulting in the loss of the tyrosine phosphorylation of tumor necrosis factor receptor-associated protein 1 (TRAP1) and receptor-interacting protein 1, two crucial TNF signaling molecules. Functional analyses revealed that knockdown of TRAP1 facilitated cell death induced by TRAIL or doxorubicin in ALK(+) ALCL cells. This suggests that down-regulation of TRAP1 in combination with TRAIL or doxorubicin might be a potential novel therapeutic strategy for ALK(+) ALCL. These findings demonstrated that our strategy allowed the identification of novel proteins downstream of NPM-ALK that contribute to the maintenance of neoplastic phenotype and holds great potential for future studies of cellular tyrosine kinases in normal states and diseases.
Wu
Fang
F
double daggerDepartment of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.
Wang
Peng
P
Zhang
Jingdong
J
Young
Leah C
LC
Lai
Raymond
R
Li
Liang
L
D000595:Amino Acid Sequence; D002460:Cell Line; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000378:metabolism*; D008969:Molecular Sequence Data; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D020543:Proteome / Q000032:analysis*; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D019014:fas Receptor / Q000378:metabolism*
D010750:Phosphoproteins; D020543:Proteome; D034741:RNA, Small Interfering; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor; C107023:p80(NPM-ALK) protein; D011505:Protein-Tyrosine Kinases
Anal Chem. 2008 Jun 15;80(12):4696-710
18479145
Oncogene. 2004 Jul 15;23(32):5426-34
15184887
Oncogene. 2008 Apr 24;27(19):2728-36
17998938
Nat Biotechnol. 2005 Jan;23(1):94-101
15592455
Immunity. 2009 Jan 16;30(1):143-54
19144319
Mol Cell Proteomics. 2005 Sep;4(9):1240-50
15951569
Am J Pathol. 2009 Feb;174(2):361-70
19131589
Blood. 2007 Oct 1;110(7):2600-9
17537995
Oncogene. 2007 Aug 16;26(38):5606-14
17353907
Mol Cell Biol. 1998 Dec;18(12):6951-61
9819383
Front Biosci. 2008 May 01;13:5094-107
18508572
Nat Methods. 2007 Mar;4(3):207-14
17327847
Blood. 2000 Dec 1;96(12):3681-95
11090048
EMBO Rep. 2003 Jun;4(6):623-7
12776182
J Biol Chem. 2010 Jan 1;285(1):95-103
19887368
Oncogene. 2003 Aug 21;22(35):5399-407
12934099
Br J Haematol. 1990 Feb;74(2):161-8
2156548
Eur J Cancer Prev. 2008 Apr;17(2):169-77
18287875
Blood. 1988 Jul;72(1):234-40
3260522
Blood. 2009 Mar 19;113(12):2776-90
18845790
PLoS Biol. 2007 Jul;5(7):e172
17579517
Nat Protoc. 2006;1(4):1929-35
17487178
Genomics. 1997 Sep 1;44(2):179-87
9299234
Blood. 2009 Jul 9;114(2):360-70
19423729
Mol Cell Proteomics. 2010 Jan;9(1):84-99
19770167
Mol Cell Proteomics. 2003 Nov;2(11):1234-43
14506206
Mol Cell Proteomics. 2005 Jun;4(6):721-30
15659558
Science. 1995 Jan 20;267(5196):316-7
7824924
J Clin Oncol. 2002 Sep 1;20(17):3691-702
12202671
Cell Signal. 2006 Sep;18(9):1528-35
16442262
Cancer Res. 2001 Mar 1;61(5):2194-9
11280786
Blood. 2006 Oct 15;108(8):2780-8
16835382
Blood. 1989 Jun;73(8):2155-64
2525056
Cell Signal. 2007 Apr;19(4):740-7
17110082
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8
12522270
Blood. 2007 Sep 1;110(5):1621-30
17416736
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1488-93
17242355
Cancer Res. 2007 May 1;67(9):4278-86
17483340
Mol Cell Proteomics. 2008 May;7(5):971-80
18212344
J Proteome Res. 2008 Sep;7(9):4058-69
18707149
J Proteome Res. 2008 Dec;7(12):5167-76
19367720
Oncogene. 2007 Feb 8;26(6):813-21
16909118
Anal Biochem. 2008 Jun 15;377(2):234-42
18396144
Leukemia. 2008 Nov;22(11):2091-6
18685609
Mol Cell Proteomics. 2007 Feb;6(2):283-93
17114649
J Immunol. 2002 Jan 1;168(1):466-74
11751994
J Biol Chem. 2000 Jan 14;275(2):1365-70
10625686
J Biol Chem. 1995 Feb 24;270(8):3574-81
7876093
Nat Biotechnol. 2002 Mar;20(3):301-5
11875433
Blood. 2004 Feb 15;103(4):1464-71
14563642
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6
8633037
EMBO J. 2008 Mar 19;27(6):852-64
18309296
Br J Haematol. 2006 Oct;135(1):26-32
16939498
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14212-7
12381793
Anal Chem. 2004 May 15;76(10):2763-72
15144186
Anal Chem. 2009 Feb 1;81(3):1049-60
19178338
J Proteome Res. 2008 Jan;7(1):311-8
18034455
Mol Cell Proteomics. 2005 Sep;4(9):1358-69
15972895
Mol Cell Proteomics. 2008 Apr;7(4):645-60
18006492
Cell Signal. 2007 Nov;19(11):2237-46
17693058
Exp Hematol. 2003 Apr;31(4):309-15
12691918
Mol Cancer Ther. 2006 Aug;5(8):2115-20
16928833
Blood. 1988 Sep;72(3):1045-7
3416066
Oncogene. 2002 Feb 7;21(7):1038-47
11850821
Blood. 2005 May 1;105(9):3722-30
15650054
Mol Cell Proteomics. 2006 May;5(5):914-22
16452087
J Biol Chem. 2008 Feb 15;283(7):3743-50
18070884
J Biol Chem. 2003 Aug 8;278(32):30028-36
12748172
Anal Chem. 2005 Aug 15;77(16):5144-54
16097752
Mol Cell Biochem. 2007 Jul;301(1-2):115-22
17216128
Nat Biotechnol. 2001 Apr;19(4):379-82
11283599
Science. 1994 Mar 4;263(5151):1281-4
8122112
Leukemia. 2008 Aug;22(8):1595-603
18509351
Trends Biochem Sci. 2005 Mar;30(3):151-9
15752987
Blood. 2000 Dec 15;96(13):4319-27
11110708
Anal Chem. 2004 Jul 15;76(14):3935-43
15253627
Cancer Res. 2001 Sep 1;61(17):6517-23
11522649
Mol Cell Proteomics. 2005 Jul;4(7):873-86
15858219
J Cell Biol. 1994 Dec;127(6 Pt 1):1515-26
7798308